Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides

Sexually Transmitted Diseases

Volumn 36, Issue 3 SUPPL., 2009, Pages

  Keller, Marla J ^a   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GREEN FLUORESCENT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE; NEUTRALIZING ANTIBODY; RECOMBINANT ADENOVIRUS 26 VECTOR; RECOMBINANT ADENOVIRUS 48 VECTOR; RECOMBINANT ADENOVIRUS 5 VECTOR; UNCLASSIFIED DRUG; ADENOVIRUS VECTOR; PRO 2000; RANTES;

ANTIVIRAL ACTIVITY; ASSAY; DRUG EFFICACY; EPITHELIUM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; OUTCOME ASSESSMENT; REVIEW; SEMINAL PLASMA; SEXUALLY TRANSMITTED DISEASE; SPERM; TREATMENT OUTCOME; UTERINE CERVIX MUCUS; VAGINA CONTRACEPTION; VAGINA EPITHELIUM; VAGINA MUCOSA; VALIDATION STUDY; VIRUS ISOLATION; VIRUS TRANSMISSION; CLADISTICS; EX VIVO STUDY; INFECTION PREVENTION; NONHUMAN; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTI-INFECTIVE AGENTS; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; DRUG DESIGN; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; SEXUALLY TRANSMITTED DISEASES, VIRAL; TREATMENT OUTCOME; VAGINA;

EID: 62849100828     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e318199417d     Document Type: Review

References (23)

1. Trapp S, Turville SG, Robbiani M. Slamming the door on unwanted guests: Why preemptive strikes at the mucosa may be the best strategy against HIV. J Leukoc Biol 2006; 80:1076-1083.
2. Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007; 13:857-861.
3. Bobardt MD, Chatterji U, Selvarajah S, et al. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol 2007; 81:395-405.
4. Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257-270.
5. Patterson GH, Lippincott-Schwartz J. A photoactivatable GFP for selective photolabeling of proteins and cells. Science 2002; 297: 1873-1877.
6. Marechal V, Clavel F, Heard JM, et al. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol 1998; 72:2208-2212.
7. Campbell EM, Perez O, Melar M, et al. Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology 2007; 360: 286-293.
8. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306:485-487.
9. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438:99-102.
10. Dezzutti CS, James VN, Ramos A, et al. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 2004; 48:3834-3844.
11. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20:F9-F13.
12. Cohen MS, Pilcher CD. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis 2005; 191:1391-1393.
13. Cheshenko N, Keller MJ, MasCasullo V, et al. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 2004; 48:2025-2036.
14. Munch J, Rucker E, Standker L, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007; 131:1059-1071.
15. Patel S, Hazrati, E, Cheshenko, N, et al. Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis 2007; 196:1394-1402.
16. Lai BE, Xie YQ, Lavine ML, et al. Dilution of microbicide gels with vaginal fluid and semen simulants: Effect on rheological properties and coating flow. J Pharm Sci 2008; 97:1030-1038.
17. Keller MJ, Zerhouni-Layachi B, Cheshenko N, et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: A double-blind placebo-controlled trial. J Infect Dis 2006; 193:27-35.
18. Gilbert PB, DeGruttola VG, Hudgens MG, et al. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: Issues involving surrogate end points in phase 3 trials. J Infect Dis 2003; 188:179-193.
19. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-1649.
20. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650-1660.
21. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm? Science 2007; 318:1048-1049.
22. Steinbrook R. One step forward, two steps back-will there ever be an AIDS vaccine? N Engl J Med 2007; 357:2653-2655.
23. Liu J, Ewald BA, Lynch DM, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 2008; 82:4844-4852.